A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
- 286 Downloads
AUY922 is a novel heat shock protein inhibitor with preclinical activity in pancreatic cancer. This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.
In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m2 IV weekly. The primary endpoint was disease control rate (objective response and stable disease ≥16 weeks).
Twelve patients were accrued, all of whom received treatment. At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %). Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease. The median progression-free survival was 1.6 months, and the median overall survival was 2.9 months.
AUY922 was not associated with significant efficacy in previously treated patients with advanced pancreatic cancer.
KeywordsPancreatic cancer AUY922 Phase II
This study was funded by a grant from Novartis. Novartis did not contribute to the data analysis, interpretation, or manuscript writing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no relevant conflicts of interest.
- 11.Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26:4508Google Scholar
- 12.Gill S, Ko YJ, Cripps C et al (2014) PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol 32(5s):4022Google Scholar
- 15.Pratt W, Toft D (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 228:111–133Google Scholar
- 17.Novartis AUY922 Investigator’s Brochure, July 2010Google Scholar
- 21.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
- 28.Phase II study of MEDI4736 monotherapy or in combinations with tremelimumab in metastatic pancreatic ductal carcinoma. NCT02558894Google Scholar